Table 5.
Antibiotic susceptibility profile of resistant bacterial isolates among the study participants.
| Antibiotics | Total (N) | Resistant n (%) |
|---|---|---|
| MRSA (N = 12) | ||
| Gentamicin | (N = 12) | 4 (33.3%) |
| Ciprofloxacin | (N = 12) | 4 (33.3%) |
| TMP/SMX | (N = 12) | 4 (33.3%) |
| Cefuroxime | (N = 12) | 12 (100.0%) |
| Oxacillin | (N = 12) | 12 (100.0%) |
| Penicillin | (N = 12) | 12 (100.0%) |
| Vancomycin | (N = 12) | 0 (0.0%) |
| Teicoplanin | (N = 12) | 0 (0.0%) |
| ESBL (N = 37) | ||
| Gentamicin | (N = 37) | 5 (13.5%) |
| Amikacin | (N = 37) | 5 (13.5%) |
| Ciprofloxacin | (N = 37) | 8 (21.6%) |
| Levofloxacin | (N = 37) | 8 (21.6%) |
| TMP/SMX | (N = 37) | 13 (35.1%) |
| Cefotaxime | (N = 37) | 37 (100.0%) |
| Cefepime | (N = 37) | 37 (100.0%) |
| Ampicillin | (N = 37) | 37 (100.0%) |
| Piperacillin-tazobactam | (N = 37) | 24 (64.9%) |
| Ceftazidime | (N = 37) | 37 (100.0%) |
| Imipenem | (N = 37) | 0 (0.0%) |
| Meropenem | (N = 37) | 0 (0.0%) |
| Cefuroxime | (N = 37) | 37 (100.0%) |
| Ceftriaxone | (N = 37) | 37 (100.0%) |
| Amoxicillin-clavulanate | (N = 37) | 17 (45.9%) |
| Colistin | (N = 37) | 0 (0.0%) |
| MDR (N = 42) | ||
| Gentamicin | (N = 37) | 23 (62.2%) |
| Amikacin | (N = 42) | 27 (64.3%) |
| Ciprofloxacin | (N = 42) | 30 (71.4%) |
| Levofloxacin | (N = 42) | 30 (71.4%) |
| TMP/SMX | (N = 37) | 23 (62.2%) |
| Cefotaxime | (N = 31) | 31 (100.0%) |
| Cefepime | (N = 42) | 42 (100.0%) |
| Ampicillin | (N = 31) | 31 (100.0%) |
| Piperacillin-tazobactam | (N = 42) | 42 (100.0%) |
| Ceftazidime | (N = 42) | 42 (100.0%) |
| Imipenem | (N = 42) | 42 (100.0%) |
| Meropenem | (N = 42) | 42 (100.0%) |
| Cefuroxime | (N = 31) | 31 (100.0%) |
| Ceftriaxone | (N = 31) | 31 (100.0%) |
| Amoxicillin-clavulanate | (N = 31) | 31 (100.0%) |
| Colistin | (N = 38) | 0 (0.0%) |
MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended-spectrum beta-lactamase-producing organisms; MDR, multidrug-resistant organisms; TMP/SMX, trimethoprim/sulfamethoxazole. The intermediate group was included in the sensitive group.